Pakistan Business News API

{
    "totalArticles": 323542,
    "articles": [
        {
            "id": "371baccd60d543f258ca6d2440727313",
            "title": "Pre-launch bookings open for the new BMW X6 M60i xDrive.",
            "description": "+++ Roaring V8 performance with an unmistakable road presence. +++ 0-100 in just 4.3 seconds. +++ Available for pre-booking across authorized BMW India dealership network. Customers can also register their interest on BMW India website. +++",
            "content": "Gurugram. BMW India will open pre-launch bookings for the new BMW X6 M60i xDrive at 1930 Hrs today, 22 May 2026. This performance-led luxury Sports Activity Coupe will be available in the country as a Completely Built-Up Unit (CBU) model and can be p... [1278 chars]",
            "url": "https://www.press.bmwgroup.com/india/article/detail/T0458043EN/pre-launch-bookings-open-for-the-new-bmw-x6-m60i-xdrive",
            "image": "https://mediapool.bmwgroup.com/cache/P9/202605/P90642193/P90642193-the-new-bmw-x6-m60i-xdrive-05-2026-2100px.jpg",
            "publishedAt": "2026-05-22T11:08:59Z",
            "lang": "en",
            "source": {
                "id": "65979f99b0b1eced938d64cf18f3242a",
                "name": "BMW Group",
                "url": "https://www.press.bmwgroup.com"
            }
        },
        {
            "id": "6dca25fc0836ff3a153fc67f53590477",
            "title": "Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss",
            "description": "TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an  in vivo",
            "content": "TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) fo... [14113 chars]",
            "url": "https://investor.regeneron.com/news-releases/news-release-details/otarmenitm-lunsotogene-parvec-receives-ema-filing-acceptance",
            "image": "https://regeneronpharmaceuticalsinc.gcs-web.com/static-files/b39477e0-886d-48f7-bba0-52cf365365ea",
            "publishedAt": "2026-05-22T11:05:52Z",
            "lang": "en",
            "source": {
                "id": "1529ddc3c8b1ec394b5ee8801ae7943d",
                "name": "Regeneron",
                "url": "https://investor.regeneron.com"
            }
        },
        {
            "id": "7b1f8cbe9c5da3c76214911855e3ff94",
            "title": "AVISTA HEALTHCARE PARTNERS SIGNS DEFINITIVE AGREEMENT TO ACQUIRE SANOTACT GROUP",
            "description": "/PRNewswire/ -- Avista Healthcare Partners (\"Avista\"), a leading private equity firm focused exclusively on healthcare, and Damier Group (\"Damier\") have signed...",
            "content": "Damier Group joins as strategic co-investor alongside existing investor FLOTTE Beteiligungen GmbH (\"FLOTTE\") to reinvest alongside the new shareholders\nNEW YORK, May 22, 2026 /PRNewswire/ -- Avista Healthcare Partners (\"Avista\"), a leading private eq... [5604 chars]",
            "url": "https://www.prnewswire.com/news-releases/avista-healthcare-partners-signs-definitive-agreement-to-acquire-sanotact-group-302779733.html",
            "image": "https://www.prnewswire.com/content/dam/prnewswire/icons/2019-Q4-PRN-Icon-32-32.png",
            "publishedAt": "2026-05-22T11:00:00Z",
            "lang": "en",
            "source": {
                "id": "4e4307a07d2ce1e31acaf932954d3dd9",
                "name": "PR Newswire",
                "url": "https://www.prnewswire.com"
            }
        }
    ]
}